NVDA
NVIDIA
-- 142.620 TSLA
Tesla
-- 406.580 PLTR
Palantir
-- 78.980 AAPL
Apple
-- 222.780 MSTR
MicroStrategy
-- 353.670 
$Ocugen (OCGN.US)$ Smart financial app learned that swayamp...
$Ocugen (OCGN.US)$
Smart financial app learned that swayampakula ramakanth, an analyst at H.C. Wainwright, published a research report, believing that the potential new crown vaccine will become ocugen（ OCGN.US ）The target price is $12, which is more than 40% higher than the current share price. Ramakanth believes the company's $47 million cash position should be enough to support its operations through 2023. Assuming regulatory approval for the new coronal vaccine covaxin from its partner Bharat biotech, the analyst expects revenue of $280 million and diluted earnings per share of $1.10 in 2021. Ocugen has signed an agreement with Bharat to introduce covaxin into the United States. The company will supervise the clinical development of the vaccine, obtain regulatory approval, and undertake all commercialization work in the United States. In return, ocugen will make a 45% profit. It is reported that covaxin has been authorized for emergency use in India, and the mid-term analysis of phase 3 clinical trials shows that its effectiveness is 81%.
Smart financial app learned that swayampakula ramakanth, an analyst at H.C. Wainwright, published a research report, believing that the potential new crown vaccine will become ocugen（ OCGN.US ）The target price is $12, which is more than 40% higher than the current share price. Ramakanth believes the company's $47 million cash position should be enough to support its operations through 2023. Assuming regulatory approval for the new coronal vaccine covaxin from its partner Bharat biotech, the analyst expects revenue of $280 million and diluted earnings per share of $1.10 in 2021. Ocugen has signed an agreement with Bharat to introduce covaxin into the United States. The company will supervise the clinical development of the vaccine, obtain regulatory approval, and undertake all commercialization work in the United States. In return, ocugen will make a 45% profit. It is reported that covaxin has been authorized for emergency use in India, and the mid-term analysis of phase 3 clinical trials shows that its effectiveness is 81%.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day
一跌送你去荷兰 : Let's wait for a wave to come up tonight
71331754 : All is potential. Who knows what will happen? It is still not approved by FDA. who knows what is the market portion when it is approved.
71331754 : Bullshit stock keeps dropping. Really angry. Once it returns to the purchase price, sell all of them.